Bend Research has added an Xcelodose 600S powder micro-dosing system, the company said, allowing it to fill capsules for inhalation development projects with low dose weights. The company notes that, “Precision capsule fill capability is imperative for dry powder inhalation drug products.” Bend was recently acquired by Capsugel, which manufactures the Xcelodose line.
With the Rapid Advancement of Preclinical Compound initiative now in place at Bend, the company says that the Xcelodose technology will allow it to advance inhalation drug development projects “from proof of concept through Phase 2 in 20 weeks or less.”
Bend President Jim Nightingale commented, “As leaders in bioavailability enhancement and modified release, we are utilizing complementary technologies at Capsugel and Bend Research to improve our collective offerings and help our clients advance their best medicines. For example, integrating Bend Research’s expertise in particle engineering for inhalation, Capsugel’s Xcelodose technology, and Capsugel’s expertise in development of customized dry powder inhalation (DPI) capsules will do just that in the area of inhalation drug development and delivery.”
Read the Bend press release.
